Original Article
Effects of chondroitin sulfate on modulation of MMPs and TIMP-1 in a monosodium iodoacetate-induced osteoarthritis model

In-Hwan Joo1, Ga-Yul Min1, Hak-Joo Choi2, Boo-Yong Sim2, Hwa-Young Kim3, Jin Kim3, Joong-Gu Ji4, Jung-Hwan Kim5, Dong-Hee Kim1,2

1Department of Pathology, College of Oriental Medicine, Daejeon University, Daejeon, Republic of Korea; 2Traditional and Biomedical Research Center, Daejeon University, Daejeon, Republic of Korea; 3Juyeong NS Co., Ltd. Seoul, Republic of Korea; 4Department of Oriental Health Care, Joongbu University, Republic of Korea; 5JoongWon Oriental Medicine Research and Development Office, Daegu, Republic of Korea

Received June 7, 2018; Accepted September 11, 2018; Epub October 15, 2018; Published October 30, 2018

Abstract: Osteoarthritis (OA) is caused by damage to cartilage and chondrocytes and is characterized by inflammatory cytokine secretion during disease progression. Secreted cytokines regulate the expression of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs), which are involved in chondrocyte repair. The glycosaminoglycan chondroitin sulfate (CS), a component of various connective tissues, stimulates chondrocytes to regenerate cartilage and prevents destruction. CS is currently being used in clinical practice to treat OA, but the mechanism by which CS influences OA is unclear. In this study, the effect of CS on MMPs and TIMP-1 was investigated in OA animal models. The OA models were treated with 300, 600, and 900 mg/kg CS for 6 weeks. After 2 weeks of treatment, OA was induced by the injection of monosodium iodoacetate into the knee joint capsule of Sprague-Dawley rats. Serum levels of MMPs and TIMP-1 were measured by an enzyme-linked immunosorbent assay and mRNA levels were quantitated by quantitative real-time polymerase chain reaction using cartilage tissue isolated from the joints. CS (900 mg/kg) significantly down-regulated the levels of MMP-2 (-27%), MMP-3 (-19%), MMP-9 (-40%), and MMP-13 (-15%) and the mRNA levels of MMP-2 (-29%), MMP-3 (-15%), MMP-9 (-29%), and MMP-13 (-17%). CS also significantly up-regulated TIMP-1 at the mRNA (28%) and protein (24%) level. Histopathologic and radiographic analyses showed that the cartilage and synovium were effectively preserved. Accordingly, CS regulates MMP and TIMP-1 levels, thereby reducing decomposition of the chondrocyte matrix and protecting chondrocytes. Thus, CS can be used to treat OA.

Keywords: Osteoarthritis, chondroitin sulfate, monosodium iodoacetate, matrix metalloproteinase, and tissue inhibitor of metalloproteinase

Introduction

Osteoarthritis (OA) is the most common cause of joint pain, affecting about 15% of the population, and is considered a major public health problem worldwide. It is an inflammatory disease that is common in the elderly and women, causing joint and cartilage damage [1-3].

Recent studies have shown that OA progression is associated with the secretion of inflammatory cytokines, which increase matrix metalloproteinase (MMP) activity [4, 5]. MMPs cause severe damage to cartilage and chondrocytes via degradation of collagen and proteoglycans, components of cartilage [6, 7]. Tissue inhibitors of metalloproteinases (TIMPs) block chondrocyte damage by inhibiting MMP activity [8, 9].

Chondroitin sulfate (CS), a glycosaminoglycan, is a major component of the extracellular matrix of many connective tissues, including cartilage, bone, skin, ligaments, and tendons. It enhances homogenization/catabolism balance of the extracellular cartilage matrix, reduces the action factor, and reduces the absorption characteristics of subchondral osteoblasts [10-12]. The anti-inflammatory effects of CS and its ability to reduce MMP-3 and MMP-13 levels in OA induced by interleukin-1β have been demonstrated in several studies [13-19]. However, stud-
Effects of chondroitin sulfate on osteoarthritis

ies of cartilage damage and recovery in monosodium iodoacetate (MIA)-induced OA are lacking.

The MIA experimental model involves the destruction of articular cartilage by inducing the persistent infiltration of synoviocytes and inflammatory cells and is commonly used to assess pain associated with OA [20, 21]. This model is widely used for the pharmacological evaluation of new drug treatments [22].

In this study, we hypothesized that CS could down-regulate MMPs and up-regulate TIMP-1 to protect against and repair cartilage damage. Accordingly, we investigated the effect of CS on serum protein levels, mRNA expression levels, and histological properties in the MIA-induced OA model.

Materials and methods

Animals

Male Sprague-Dawley rats (170-200 g, 6 weeks old) were obtained from RaonBio Inc. (Yong-in, Korea). The rats were acclimated for 10 days and housed under controlled conditions with a temperature of 22 ± 2°C, humidity of 55 ± 15%, a 12-hour light/12-hour dark cycle, and fresh-air ventilation (10-15 times/hour). The rats were housed in solid-bottom cages with free access to food and water. All experimental procedures complied with the NIH Guide for the Care and Use of Laboratory Animals and the Korean National Animal Welfare Law. The experimental animal facility and study protocols were approved by the Institutional Animal Care and Use Committee of Daejeon University (DJUARB2017-020).

Test material doses and groups

CS manufactured by Internacional Farmaceutica Argentina S.A. (Buenos Aires, Argentina) was obtained from Ju Yeong NS (Seoul, Korea). CS was obtained from bovines and contained purified chondroitin sulfate sodium at a concentration of not less than 90%, calculated on a dry basis. Before starting the experiment, the rats were randomly assigned to a normal control group (NC group, n = 10), an OA control group (OAC group, n = 10), and CS treatment groups receiving 300 mg/kg (300 group, n = 10), 600 mg/kg (600 group, n = 10), and 900 mg/kg (900 group, n = 10). In the NC and OAC groups, animals were orally administered distilled water, and CS treatment groups were orally administered the appropriate dose for 6 weeks.

Osteoarthritis induction

After 2 weeks of oral administration, a single injection of 50 µL of sterile 0.9% saline containing 3 mg/kg MIA (Sigma-Aldrich, St. Louis, MO, USA) was injected into the intra-articular space of the right knee using a 31-gauge ultrafine insulin syringe (Becton Dickinson, Franklin Lakes, NJ, USA) inserted to a depth of approximately 2-3 mm. This step was performed under anesthesia induced by an intraperitoneal injection of ketamine and xylazine [23]. The NC group received an equivalent volume of saline instead of MIA. After the injection of MIA, the rats with MIA-induced OA received distilled water or the same doses of CS for 4 weeks. The treatment groups received daily oral doses of CS for a total of 6 weeks. The administration volumes were 2 mL for all experimental groups.

Sample collection

After 6 weeks of treatment, all rats were euthanized after being anesthetized by an intraperitoneal injection of ketamine and xylazine. Serum and knee cartilage were separated and frozen at -80°C until use.

ELISA

The levels of matrix metalloproteinases (MMPs; MMP-2, MMP-3, MMP-9, and MMP-13) and TIMP-1 in the serum were measured using Enzyme-linked Immunosorbent Assay (ELISA) Kits (Elabscience, Houston, Texas, USA). Each serum sample and standard was reacted at 37°C for 90 minutes. After the reaction, washing was performed three times using washing buffer, and then 100 µL of detection antibody was added, followed by reaction at 37°C for 60 minutes. After washing, 100 µL of HRP conjugate was added and reacted at 37°C for 30 minutes. After washing, 90 µL of substrate reagent was added and reacted at 37°C for 15 minutes. Finally, 50 µL of stop solution was added and absorbance at 450 nm was measured using a SpectraMax 400 (Molecular Devices, San Jose, CA, USA). Values were obtained based on the standard curve.
Effects of chondroitin sulfate on osteoarthritis

Table 1. Primer sequences

<table>
<thead>
<tr>
<th>Gene name</th>
<th>Primer sequences</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAPDH</td>
<td>5'-AGTGCCAGCTCCGCTCAT-3' (sense)</td>
</tr>
<tr>
<td></td>
<td>5'-ACCATGTAGTGGAGTCAAT-3' (antisense)</td>
</tr>
<tr>
<td>MMP-2</td>
<td>5'-TCCGGAGATCTGCTAGACAG-3' (sense)</td>
</tr>
<tr>
<td></td>
<td>5'-AGAGATGAGCAACAGCAAG-3' (antisense)</td>
</tr>
<tr>
<td>MMP-3</td>
<td>5'-AGATCCATGGAAGCGCTCG-3' (sense)</td>
</tr>
<tr>
<td></td>
<td>5'-TCAGTGCGCAAAGTCTCAAG-3' (antisense)</td>
</tr>
<tr>
<td>MMP-9</td>
<td>5'-GATCCCCAGAGCGCCATCG-3' (sense)</td>
</tr>
<tr>
<td></td>
<td>5'-GTGTGGAAGCTCACACGCCG-3' (antisense)</td>
</tr>
<tr>
<td>MMP-13</td>
<td>5'-TGCTGCAATCGAGCTCCTCAAG-3' (sense)</td>
</tr>
<tr>
<td></td>
<td>5'-CTGCGAATCGGACTGGTTA-3' (antisense)</td>
</tr>
<tr>
<td>TIMP-1</td>
<td>5'-CAGCGTGGATCCTTTCG-3' (antisense)</td>
</tr>
<tr>
<td></td>
<td>5'-CAGCGTGGATCCTTTCG-3' (antisense)</td>
</tr>
</tbody>
</table>

GAPDH, glyceraldehyde 3-phosphate dehydrogenase; MMPs, matrix metalloproteinases; TIMPs, tissue inhibitor of metalloproteinases.

Quantitative real-time polymerase chain reaction analysis

Samples for RNA extraction were obtained from the cartilage tissue of rats by cryogenic grinding, and total RNA was extracted using the Easy-spin (DNA free) Total RNA Extraction Kit (Intron Biotechnology Inc., Seoul, Korea) according to the manufacturer’s instructions. A total of 1 μg of total RNA was reverse transcribed in a volume of 20 μL using oligo (dT) primers, with the enzyme and buffer supplied in the AccuPower CycleScript RT PreMix (Bioneer, Daejeon, Korea). Quantitative real-time polymerase chain reactions (PCRs) were performed using a Rotor-Gene Q device (Qiagen, Hilden, Germany); the primers are shown in Table 1. The QuantiTect SYBR Green PCR Kit (Qiagen) was used for real-time PCR. The final volume of the reaction mixture was 25 μL, including 2 μL of cDNA template, 12.5 μL of Master Mix, 1 μL of each primer (10 μM stock solution), and 8.5 μL of sterile distilled water. The thermal cycling profile consisted of a pre-incubation step at 95°C for 10 minutes, followed by 40 cycles at 95°C (15 seconds) and 60°C (60 seconds). Relative quantitative evaluations of MMP-2, MMP-3, MMP-9, MMP-13, and TIMP-1 were performed using a threshold value of 25 cycles.

Histological analysis

Tissue specimens from the right knee joints were removed, fixed in 10% formalin, decalcified in paraffin, and serially sectioned at a thickness of 7 μm. The tissue sections were then stained with hematoxylin and eosin (H&E). Histological changes were examined by light microscopy (Axioskop 40; Carl Zeiss, Oberkochen, Germany) and images were obtained (AxioCam ICc1; Carl Zeiss). Cartilage degeneration of the medial tibial plateau was evaluated using the Osteoarthritis Research Society International (OARSI) score [24]. This scoring system measures the medial tibia plateau on a scale of 0-5 (0 = no degeneration, 1 = mild degeneration at the surface, 2 = slightly extended degeneration in the upper center, 3 = moderate degeneration in the median area, 4 = extended deep degeneration, and 5 = severe degeneration). All sections were observed and evaluated by three authors.

Morphological analysis

The microarchitecture of knee joints at 0.6-2.1 mm from the growth plate of the distal femur was scanned using a micro-computed tomography (micro-CT) system (Sky-Scan 1076; SkyScan, Aartselaar, Belgium). The X-ray source was set to a voltage of 50 kV and a current of 200 μA, and the beam was filtered using a 0.5-mm aluminum filter. The scanning angular rotation was 180° with an angular step of 0.5° [25]. The voxel size was fixed at 8.9 μm. The morphometric indices of the cartilage region were determined using CTAn (SkyScan 1076; SkyScan). All sections were observed and evaluated by three authors.

Data analysis

All results are reported as mean ± standard deviation. Results were analyzed by paired t-tests for two-group comparisons and by one-way ANOVA for comparisons among more than two groups using SPSS, Version 24.0 (IBM, Armonk, NY, USA). Values of p < 0.05, 0.01, and 0.001 were considered significant.

Results

Effects of CS on biomarker levels in the serum

The NC and OAC groups exhibited significant differences (p < 0.01) in the levels of MMPs and TIMP-1. After treatment with CS, the 600 and 900 groups showed significant decreases (p < 0.05) in levels of MMP-2 (Figure 1A),...
MMP-3 (Figure 1B) and MMP-9 (Figure 1C) and a significant increase (p < 0.05 and 0.01) in TIMP-1 (Figure 1E). However, only MMP-13 (Figure 1D) exhibited a significant decrease (p < 0.05) in the 900 group.

**Effects of CS on biomarker expression at the mRNA level**

The OAC group exhibited significantly higher mRNA expression levels of MMP-2, MMP-3, MMP-9, and MMP-13 (p < 0.001), and significantly lower TIMP-1 levels (p < 0.01) compared to those in the NC group (Figure 2). After treatment with CS, the 600 and 900 groups showed significant down-regulation (p < 0.05) of MMP-2 (Figure 2A), MMP-3 (Figure 2B), MMP-9 (Figure 2C), and MMP-13 (Figure 2D). Additionally, TIMP-1 (Figure 2E) mRNA expression was significantly up-regulated (p < 0.05).

**Effects of CS on OA histopathology**

Compared to the NC group, the OAC and CS groups showed decreases in CS between the cartilage (yellow circle in Figure 3) and decreased cartilage between the femur and tibia. However, in the CS group, the amount of CS was maintained in a dose-dependent manner and CS levels around the joints were greater.

**Figure 1.** The effects of CS on serum levels of MMPs and TIMP-1 in a monosodium iodoacetate-induced osteoarthritis model. Levels are expressed as absolute values (means ± standard deviation, n = 10/group) (++p < 0.01, +++p < 0.001 compared to the NC group, *p < 0.05, **p < 0.01, ***p < 0.001 compared to the OAC group). Matrix metalloproteinase-2 (MMP-2) (A), MMP-3 (B), MMP-9 (C), MMP-13 (D), tissue inhibitor of metalloproteinase-1 (TIMP-1) (E).
than those in the OAC group (Figure 3A). Based on Safranin-O staining, proteoglycan (yellow arrow in Figure 3B) staining in the periphery of the cartilage and synovial membrane in the OAC group and CS group were not distributed evenly compared to that in the NC group. In the CS group, proteoglycan levels around the cartilage and synovial membrane were higher than those in the OAC group, which showed a lack of proteoglycans in these regions (Figure 3B). Additionally, the OARSI histological score was significantly higher in the OAC group than in the NC group (p < 0.001). After treatment with CS, the 600 and 900 groups showed significantly lower OARSI scores (p < 0.001) compared to that in the OAC group (Figure 3C).

**Effects of CS on femur morphology and articular cartilage volume**

Compared to the NC group, the OAC group and the CS group showed marked decreases in the cartilage volume (purple area in the yellow circle in Figure 4) and severe bone destruction in the lower femur region. There were no significant differences in bone destruction between the CS group and the OAC group, but the cartilage volume was better preserved in the CS group.
Discussion

OA is one of the most common joint diseases in adults. It is accompanied by a gradual loss of joint cartilage and secondary changes and symptoms associated with local joints. It is characterized mainly by local degenerative changes of the articular cartilage, hypertrophy of the cartilage, excessive bone formation of the surrounding osteochondral region, and deformation of the joint, resulting in repeated pain, arthroscopic instinct, and gradual movement disorders [26, 27].

Currently, OA is treated with surgery or medication, with the aim of relieving pain and symptoms. Analgesics, nonsteroidal anti-inflammatory drugs, and symptomatic slow-acting drugs in OA are prescribed [28], but their use has been limited owing to their poor therapeutic efficacy and side effects. Therefore, better materials for OA treatment are needed.
Effects of chondroitin sulfate on osteoarthritis

CS occurs naturally in the extracellular matrix of the articular cartilage and is composed of N-acetylgalactosamine and glucuronic acid, which are glycosaminoglycans composed of long unbranched polysaccharides with a repeating disaccharide unit [29]. They stimulate chondrocytes to produce proteoglycans and collagen, regenerate cartilage, and prevent cartilage destruction [30, 31]. In this study, the efficacy of CS for the prevention and recovery of cartilage destruction, which is a factor in OA, was evaluated.

MMPs are the main mediators of cartilage destruction. They can degrade all components of the extracellular matrix. Damaged chondrocytes in OA produce pro-inflammatory cytokines, such as IL-1β and TNF-α, creating an inflammatory environment, and these cytokines increase the synthesis of MMPs [32, 33]. In this study, oral administration of CS reduced the levels of MMPs by greater than 15% compared to levels in the OAC group (Figure 1A-D), and mRNA expression levels of MMPs were also down-regulated by greater than 15% compared to levels in the OAC group (Figure 1E).

TIMP-1 can block the activity of all MMPs, except membrane type 1 MMP [9]. In this study, the oral administration of CS reduced the levels of TIMP-1 by greater than 24% compared to levels in the OAC group (Figure 2A-D), and the mRNA expression levels of TIMP-1 were also up-regulated by greater than 28% compared to those in the OAC group (Figure 2E).

Therefore, MMPs and TIMP-1 are potential targets for OA therapy because they play important roles in cartilage destruction [34]. CS seems to have a protective effect against cartilage destruction caused by OA. It has an inhibitory effect on MMP activity increased by OA. Based on histological and morphological analyses, cartilage deformation was greater in the OAC group than in the NC group. The CS group showed less deformation of cartilage than that in the OAC group. In addition, Safranin-O staining showed that the OAC group had more proteoglycan layer destruction than that of the NC group. The CS group showed less destruction of the proteoglycan layer than that of the OAC group. Finally, micro-CT-arthrography was used to analyze the knee joint cartilage volume. The CS group had an increased cartilage volume compared to that of the OAC group.

In this study, MMPs and TIMP-1 were examined at the protein and mRNA levels in the blood and injured cartilage tissue. CS protected damaged cartilage cells by regulating biomarkers associated with OA. These results provided additional evidence for the clinical treatment of OA using CS.

Acknowledgements

This research was supported by the RIC program of MOTIE (Ministry of Trade, Industry and Energy) at Daejeon University and was funded by Ju Yeong NS.

Address correspondence to: Dr. Dong-Hee Kim, Daejeon University, 62 Daehak-Ro, Dong-Gu, Daejeon, Republic of Korea. Tel: +82-42-280-2636; Fax: +82-42-280-2623; E-mail: dhkim@dju.kr

References


Effects of chondroitin sulfate on osteoarthritis


